Fisher Asset Management Portfolio holdings
Fisher Asset Management, LLC, operating as Fisher Investments, was founded in 1979 by Ken Fisher and is headquartered in Plano, Texas, following a relocation from Camas, Washington, in 2023. As an independent, fee-only investment adviser, it manages over $275 billion in assets for individual and institutional investors globally as of June 2024, offering tailored portfolio management through its Private Client Group and Institutional Group. Known for its active, top-down investment approach guided by a five-member Investment Policy Committee, the firm emphasizes asset allocation and has expanded internationally with offices in eight countries, including a wholly owned subsidiary, Fisher Investments Europe Limited, in London. With Ken Fisher as executive chairman and co-chief investment officer, succeeded as CEO by Damian Ornani in 2016, Fisher Investments blends a legacy of innovation with a client-first philosophy, recently spinning off its 401(k) Solutions into Fisher Retirement Solutions in 2024.
Top Buys
| 1 |
AbbVie
ABBV
|
+$1.88B |
| 2 |
Pfizer
PFE
|
+$1.41B |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$1.17B |
| 4 |
Cisco
CSCO
|
+$1.1B |
| 5 |
Novartis
NVS
|
+$984M |
Top Sells
| 1 |
Abbott
ABT
|
+$1.21B |
| 2 |
Adobe
ADBE
|
+$1.06B |
| 3 |
Stryker
SYK
|
+$955M |
| 4 |
Boston Scientific
BSX
|
+$695M |
| 5 |
Banco Santander
SAN
|
+$684M |
Sector Composition
| 1 | Technology | 23.16% |
| 2 | Financials | 17.3% |
| 3 | Industrials | 10.45% |
| 4 | Healthcare | 9.91% |
| 5 | Energy | 8.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XHR
451
Xenia Hotels & Resorts
XHR
$1.84B
| $5.93M | ﹤0.01% |
399,665
-35,328
| -8% | -$532K |
|
452
iShares Broad USD High Yield Corporate Bond ETF
USHY
$28.7B
| $5.88M | ﹤0.01% |
159,691
-11,786
| -7% | -$439K |
|
453
Dyne Therapeutics
DYN
$3.91B
| $5.86M | ﹤0.01% |
323,051
+72,986
| +29% | +$1.26M |
|
454
Broadstone Net Lease
BNL
$4.21B
| $5.69M | ﹤0.01% |
311,711
+44,184
| +17% | +$832K |
|
455
iShares S&P 100 ETF
OEF
$20.3B
| $5.64M | ﹤0.01% |
17,727
-1,493
| -8% | -$500K |
|
456
Cleveland-Cliffs
CLF
$5.54B
| $5.58M | ﹤0.01% |
659,968
-11,804
| -2% | -$135K |
|
457
iShares ESG Aware MSCI EAFE ETF
ESGD
$11.7B
| $5.54M | ﹤0.01% |
57,941
-1,344
| -2% | -$133K |
|
458
Kura Oncology
KURA
$969M
| $5.49M | ﹤0.01% |
675,305
+203,312
| +43% | +$1.75M |
|
459
State Street Financial Select Sector SPDR ETF
XLF
$54.6B
| $5.47M | ﹤0.01% |
110,747
+23
| +0% | +$1.2K |
|
460
Lockheed Martin
LMT
$120B
| $5.46M | ﹤0.01% |
9,036
+700
| +8% | +$431K |
|
461
iShares Core MSCI EAFE ETF
IEFA
$186B
| $5.43M | ﹤0.01% |
59,983
+43,995
| +275% | +$4.11M |
|
462
Myriad Genetics
MYGN
$553M
| $5.36M | ﹤0.01% |
1,190,896
-16,123
| -1% | -$84K |
|
463
Monte Rosa Therapeutics
GLUE
$1.86B
| $5.18M | ﹤0.01% |
+314,862
| New | +$6.02M |
|
464
iShares Core S&P Mid-Cap ETF
IJH
$122B
| $5.13M | ﹤0.01% |
75,965
+31,334
| +70% | +$2.17M |
|
465
Darling Ingredients
DAR
$9.86B
| $5.08M | ﹤0.01% |
82,144
| – | – |
|
466
Dr. Reddy's Laboratories
RDY
$10.8B
| $5.05M | ﹤0.01% |
364,745
-141,298
| -28% | -$1.97M |
|
467
AT&T
T
$150B
| $4.93M | ﹤0.01% |
169,895
-70,712
| -29% | -$1.89M |
|
468
Ecopetrol
EC
$32.6B
| $4.85M | ﹤0.01% |
323,521
-121,739
| -27% | -$1.54M |
|
469
Colgate-Palmolive
CL
$74.6B
| $4.85M | ﹤0.01% |
56,899
+17,697
| +45% | +$1.58M |
|
|
INVX
470
Innovex International
INVX
$1.78B
| $4.76M | ﹤0.01% |
195,314
-6,354
| -3% | -$160K |
|
471
West Pharmaceutical
WST
$25.4B
| $4.67M | ﹤0.01% |
18,638
+62
| +0.3% | +$15.4K |
|
472
iShares International Treasury Bond ETF
IGOV
$1.35B
| $4.63M | ﹤0.01% |
112,825
| – | – |
|
473
Marathon Petroleum
MPC
$86.7B
| $4.49M | ﹤0.01% |
18,369
-838
| -4% | -$169K |
|
474
Olema Pharmaceuticals
OLMA
$1.04B
| $4.47M | ﹤0.01% |
+299,756
| New | +$6.67M |
|
475
iShares Short-Term National Muni Bond ETF
SUB
$11.4B
| $4.47M | ﹤0.01% |
41,935
-2,622
| -6% | -$281K |
|
Similar funds
